CorrespondenceResearch CorrespondenceRemoval of Contrast Media From the Coronary Sinus Attenuates Renal Injury After Coronary Angiography and Intervention
Research Correspondence
Under an Elsevier user license
open archive
Cited by (0)
Please note: Dr. Sievert has received study honoraria, travel expenses, and/or consulting fees from Access Closure, AGA, Angiomed, Ardian, Arstasis, Avinger, Bridgepoint, CardioKinetix, CardioMEMS, Coherex, CSI, EndoCross, EndoTex, Epitek, Evalve, ev3, FlowCardia, Gore, Guidant, Lumen Biochemical, Kensey Nash, Kyoto Medical, Lutonix, Medinol, Medtronic, NCD, NMT, OAS, Occlutech, Osprey, Ovalis, Pathway, PendraCare, Percardia, pfm, Remon, Rox Medical, Sadra, Sorin, Spectranetics, SquareOne, Viacor, and Velocimed; and has stock options in Cardiokinetix, Access Closure, Velocimed, CoAptus, Lumen Biomedical, and Coherex. Dr. Pertile is an employee and stockholder of Osprey Medical. Dr. Kaye is a founder and stockholder of Osprey Medical.
Copyright © 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.